(Reuters) -Sanofi's CEO is under pressure to tell investors how much more he will spend on research and development (R&D) and what the likely pay-offs will be, as he seeks to boost a pipeline of future drugs and restore shareholder trust. Shares in the 108 billion euro ($117 billion) French pharmaceutical giant tumbled 15% on Oct. 27 when CEO Paul Hudson unexpectedly abandoned 2025 margin targets in order to boost the budget for testing new immunology and inflammation drugs. The market's shock reaction, compounded by a lack of details of the spending push, overshadowed Sanofi's plan to list its consumer unit, in line with an industry trend.
Sanofi CEO under pressure to woo investors after spending shock reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.